SCHEMBL21404989

SCHEMBL21404989

COCc1ncsc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25227159 0.76
SCHEMBL16502353 0.73 KDM4E (0.33)
SCHEMBL4974348 0.72
SCHEMBL22175619 0.71
SCHEMBL31419277 0.71
SCHEMBL18282488 0.71
SCHEMBL9644936 0.69 KDM4E (0.52)
SCHEMBL12866968 0.69 KDM4E (0.31)
SCHEMBL25271998 0.68
SCHEMBL31444980 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745134-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-20 EP disclosed
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-12 US disclosed
US-12539292-B2 BRM targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-03 US disclosed
EP-4537905-A2 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-04-16 EP disclosed
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2025-03-27 US disclosed
EP-3774789-B1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-03-05 EP disclosed
WO-2025016323-A1 PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-23 WO disclosed
WO-2024217500-A1 ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海赛默罗生物科技有限公司 2024-10-24 WO disclosed
EP-4436661-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
CN-118359538-A Isoquinoline compound, preparation method, pharmaceutical composition and application thereof 上海赛默罗生物科技有限公司 2024-07-19 CN disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
EP-3774789-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
CN-112166114-A BRM targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2021-01-01 CN disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 US disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 US disclosed